Lentiviral Vector EGF Overexpression Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing EGF expression and secretion in mesenchymal stem cells result in low levels of EGF protein, limiting their effectiveness in wound healing and tissue repair.
Innovation Solution
A lentiviral vector designed to overexpress EGF in mesenchymal stem cells, incorporating specific promoter sequences, translation initiation sequences, and post-transcriptional regulatory elements to enhance EGF expression and secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If mesenchymal stem cells are transduced with a lentiviral vector containing EGF gene, then EGF expression is increased, but the expression level remains low (less than 20 pg/mL in cell supernatant)
Solution Approach 1:
The patent optimizes multiple parameters of the lentiviral vector system including: using strong promoters (CMV, RSV, or SV40) to drive EGF expression; selecting appropriate polyadenylation signals (SV40 pA, BGH pA, or CAG pA); optimizing the EGF gene sequence (using mature EGF coding sequence without signal peptide); and adjusting viral multiplicity of infection (MOI) to achieve high transduction efficiency. These parameter optimizations collectively increase EGF expression from less than 20 pg/mL to over 100 pg/mL in cell supernatant.
2Quantity of substance
If conventional lentiviral vector is used for EGF gene delivery, then gene transfer is achieved, but protein secretion concentration remains very low (order of pg/mL)
Solution Approach 1:
The patent creates a composite lentiviral vector system that integrates multiple functional elements: a strong promoter region (CMV/RSV/SV40), the EGF coding sequence optimized for secretion, appropriate polyadenylation signals (SV40 pA/BGH pA/CAG pA), and lentiviral packaging signals. This composite structure synergistically enhances both gene expression and protein secretion, achieving EGF concentrations greater than 100 pg/mL in cell supernatant, which is sufficient for effective wound healing applications.
Data Source
AI summary
The disclosure provides a lentiviral vector for overexpressing Epidermal Growth Factor (EGF), a recombinant stem cell containing the lentiviral vector, and use of the lentiviral vector and the recombinant stem cell containing the lentiviral vector in the preparation of a medicament for the treatment of related diseases. The lentiviral vector of the disclosure comprises a vector plasmid, wherein the vector plasmid comprises a 5′LTR containing a ψ sequence, a 3′LTR, a target gene sequence between the 5′LTR and the 3′LTR, and a promoter sequence and a translation initiation sequence operably linked to the target gene sequence, and the target gene sequence is a nucleotide sequence encoding EGF.